Related Experiment Video

Updated: Aug 15, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K

Targeting RNA Splicing Overcomes Leukemia Resistance to BCL2 Inhibition

    Cancer Discovery
    |January 6, 2023
    PubMed

    Insights

    Inactivating RNA splicing factors improves BCL2 inhibition for acute myeloid leukemia (AML) patients. This finding offers a new therapeutic strategy for treating this challenging blood cancer.

    Area of Science:

    • Hematology
    • Molecular Biology
    • Oncology

    Background:

    • Acute myeloid leukemia (AML) is a complex blood cancer.
    • Targeting BCL2 offers a therapeutic strategy for AML.
    • RNA splicing factors play a role in cancer development.

    Purpose of the Study:

    • To investigate the role of RNA splicing factors in AML.
    • To determine if inactivating RNA splicing factors enhances BCL2 inhibition.
    • To explore novel therapeutic approaches for AML.

    Main Methods:

    • Utilized molecular biology techniques to study RNA splicing factors.
    • Assessed the impact of splicing factor inactivation on BCL2 expression.
    • Evaluated the efficacy of combined inhibition strategies in AML models.

    Main Results:

    • Inactivation of specific RNA splicing factors was observed.
    • Enhanced BCL2 inhibition was demonstrated upon splicing factor inactivation.
    • Synergistic effects were noted when combining splicing factor modulation with BCL2 inhibitors.

    Conclusions:

    • Targeting RNA splicing factors is a promising strategy to potentiate BCL2 inhibition in AML.
    • This approach may overcome resistance to BCL2-targeted therapies.
    • Further research is warranted to translate these findings into clinical practice.

    More Related Videos

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

    Published on: June 17, 2022

    3.3K
    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

    Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

    Published on: May 30, 2025

    522

    Related Concept Videos

    RNA Splicing01:32

    RNA Splicing

    Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
    56.6K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.4K
    Alternative RNA Splicing02:18

    Alternative RNA Splicing

    Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
    There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
    21.6K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.8K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.0K
    Rous Sarcoma Virus (RSV) and Cancer01:03

    Rous Sarcoma Virus (RSV) and Cancer

    Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
    RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
    5.3K